All In Biotech

Drug Trial Radar · NCT05789056

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

A Multicenter, Open Label Study of QRX003 Lotion in Subjects With Netherton Syndrome

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Mar 14, 2023

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Quoin PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Mar 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome

Conditions

  • Netherton Syndrome

Interventions

  • QRX003, 4% LotionDrug

    QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with 1-point reduction on IGATime frame: Up to week 16
  2. Proportion of subjects with 2-point reduction on IGATime frame: Up to week 16
  3. NS surface area changeTime frame: Up to week 16
  4. WI-NRS score changeTime frame: Up to week 16
  5. Assessment of subject satisfaction with treatment based on TSQMTime frame: Up to week 16
  6. Proportion of subjects requiring rescue therapyTime frame: Up to week 16
  7. Safety Assessment-AEsTime frame: Up to week 16
  8. Safety Assessment-LSRsTime frame: Up to week 16

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Site #1

    San Diego, California · Recruiting

  • Site #4

    Indianapolis, Indiana · Recruiting

  • Site #5

    Quincy, Massachusetts · Recruiting

  • Site #2

    San Antonio, Texas · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.